KOPRAN

Kopran Share Price

 

 

Start SIP in KOPRAN

Start SIP

Performance

  • Low
  • ₹146
  • High
  • ₹152
  • 52 Week Low
  • ₹123
  • 52 Week High
  • ₹222
  • Open Price₹149
  • Previous Close₹150
  • Volume272,084

Investment Returns

  • Over 1 Month + 14.32%
  • Over 3 Month -17.76%
  • Over 6 Month -19.03%
  • Over 1 Year -32.43%

Smart Investing Starts Here Start SIP with Kopran for Steady Growth!

Invest Now

Kopran Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 40.8
  • PEG Ratio
  • -0.6
  • Market Cap Cr
  • 718
  • P/B Ratio
  • 1.4
  • Average True Range
  • 6.15
  • EPS
  • 3.64
  • Dividend Yield
  • 2
  • MACD Signal
  • -3.39
  • RSI
  • 60.75
  • MFI
  • 92.52

Kopran Financials

Kopran Technicals

EMA & SMA

Current Price
₹148.79
-0.77 (-0.51%)
pointer
  • Bearish Moving Average 5
  • Bullish Moving Average 11
  • 20 Day
  • ₹138.43
  • 50 Day
  • ₹145.34
  • 100 Day
  • ₹155.66
  • 200 Day
  • ₹171.73

Resistance and Support

148.93 Pivot Speed
  • R3 156.59
  • R2 154.08
  • R1 151.44
  • S1 146.29
  • S2 143.78
  • S3 141.14

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Kopran Ltd. is a fully integrated pharmaceutical company, engaged in the manufacturing and marketing of active pharmaceutical ingredients (APIs) and finished dosage forms. The company serves global markets with a focus on innovation, quality, and regulatory compliance.

Kopran has an operating revenue of Rs. 597.22 Cr. on a trailing 12-month basis. An annual revenue growth of 1% is not great, Pre-tax margin of 8% is okay, ROE of 7% is fair but needs improvement. The company has a reasonable debt to equity of 3%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 16 which is a POOR score indicating inconsistency in earnings, a RS Rating of 22 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 74 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Kopran Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-12 Quarterly Results
2025-07-29 Quarterly Results
2025-05-15 Audited Results & Final Dividend
2025-02-11 Quarterly Results
2024-11-13 Quarterly Results
Date Purpose Remarks
2025-09-04 FINAL Rs.3.00 per share(30%)Final Dividend
View Kopran Dividend History Arrow

Kopran F&O

Kopran Shareholding Pattern

44.42%
0%
0.6%
0%
44.66%
10.32%

Kopran FAQs

Kopran share price is ₹148 As on 27 December, 2025 | 00:35

The Market Cap of Kopran is ₹718.4 Cr As on 27 December, 2025 | 00:35

The P/E ratio of Kopran is 40.8 As on 27 December, 2025 | 00:35

The PB ratio of Kopran is 1.4 As on 27 December, 2025 | 00:35

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23